Investing.com - Eton Pharmaceuticals (NASDAQ: ETON) reported first quarter EPS of $-0.030, worse than the analyst estimate of $-0.020. Revenue for the quarter came in at $8M versus the consensus estimate of $8.3M.
Eton Pharmaceuticals's stock price closed at $3.43. It is down -22.110% in the last 3 months and down -2.140% in the last 12 months.
Eton Pharmaceuticals saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Eton Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Eton Pharmaceuticals's Financial Health score is "great performance".
Check out Eton Pharmaceuticals's recent earnings performance, and Eton Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar